Aluminum-free borosilicate glass

Patent metadata

Field	Value
Publication number	US-2018079679-A1
Application number	US-201715705428-A
Country	US
Kind code	A1
Filing date	Sep 15, 2017
Priority date	Sep 22, 2016
Publication date	Mar 22, 2018
Grant date	—

Abstract

An aluminum-free borosilicate glass includes the following glass composition (in weight-% on oxide basis): 70-80 SiO 2; 8-14 B 2 O 3; 0 Al 2 O 3 ; 0-4 Na 2 O; 3-10 K 2 O; 0 Li 2 O; 3-14 sum Na 2 O+K 2 O; 0-1 CaO; 0-1 MgO; 0-1 BaO; 0-1 SrO; 0-2 sum CaO+MgO+BaO+SrO; 0-1 ZnO; 3.6-14 ZrO 2; 0-10 TiO 2; and 0.01-2.0 one or more refining agents, the weight ratio of ZrO 2 :K 2 O being in a range of 1.2:1 to 1.4:1.

First claim

What is claimed is:

1 . An aluminum-free borosilicate glass, comprising the following glass composition (in weight-% on oxide basis):
SiO 2 70-80; B 2 O 3 8-14; Al 2 O 3 0; Na 2 O 0-4; K 2 O 3-10; Li 2 O 0; sum Na 2 O+K 2 O 3-14; CaO 0-1; MgO 0-1; BaO 0-1; SrO 0-1; sum CaO+MgO+BaO+SrO 0-2; ZnO 0-1; ZrO 2 3.6-14; TiO 2 0-10; and at least one refining agent 0.01-2.0; wherein a weight ratio of ZrO 2 :K 2 O is in a range of 1.2:1 to 1.4:1.

2 . The borosilicate glass according to claim 1 , comprising the following glass composition (in weight-% on oxide basis):
SiO 2 70-78; B 2 O 3 9-13; Al 2 O 3 0; Na 2 O 0.3-3; K 2 O 4-8; Li 2 O 0; sum Na 2 O+K 2 O 4.3-11; CaO 0-0.5; MgO 0-0.5; BaO 0-0.5; SrO 0-0.5; sum CaO+MgO+BaO+SrO 0-1; ZnO 0-0.75; ZrO 2 4.8-11.2; TiO 2 0-1; and at least one refining agent 0.01-2.0; wherein the weight ratio of ZrO 2 :K 2 O is in the range of 1.2:1 to 1.4:1.

3 . The borosilicate glass according to claim 1 , wherein the weight ratio of ZrO 2 : K 2 O is in the range of 1.22:1 to 1.4:1.

4 . The borosilicate glass according to claim 1 , wherein the sum of Na 2 O+K 2 O is in a range of 3.8 to 12.5 weight-%.

5 . The borosilicate glass according to claim 1 , wherein a weight ratio of K 2 O:Na 2 O is >1.0:1.

6 . The borosilicate glass according to claim 1 , wherein the glass composition is alkaline earth free with the exception of unavoidable impurities.

7 . The borosilicate glass according to claim 1 , wherein the glass composition does not contain aluminum oxide, alkaline earth oxide, lithium oxide, zinc oxide or titanium oxide with the exception of unavoidable impurities.

8 . The borosilicate glass according to claim 1 , wherein said borosilicate glass has a maximum crystallization rate (KG max ) of ≦0.05 μm/min, measured in a crystallization range of 700-1115° C. and a temperature T (KG max ) of ≦1000° C.

9 . The borosilicate glass according to claim 1 , wherein said borosilicate glass has a hydrolytic resistance according to hydrolytic Class 1 according to ISO 720 or USP, a resistance to acids according to acid resistance class S1 according to DIN 12 116, and a resistance to alkali according to alkali resistance class A1 according to ISO 695.

10 . A primary pharmaceutical packaging, comprising:
a borosilicate glass comprising the following glass composition (in weight-% on oxide basis):
SiO 2 70-80;
B 2 O 3 8-14;
Al 2 O 3 0;
Na 2 O 0-4;
K 2 O 3-10;
Li 2 O 0;
sum Na 2 O+K 2 O 3-14;
CaO 0-1;
MgO 0-1;
BaO 0-1;
SrO 0-1;
sum CaO+MgO+BaO+SrO 0-2;
ZnO 0-1;
ZrO 2 3.6-14;
TiO 2 0-10; and
at least one refining agent 0.01-2.0;
wherein a weight ratio of ZrO 2 :K 2 O is in the range of 1.2:1 to 1.4:1.

11 . The primary pharmaceutical packaging according to claim 10 , wherein said primary pharmaceutical packaging is a container for pharmaceutical products.

12 . The primary pharmaceutical packaging according to claim 11 , wherein said container is at least one of a bottle, a vial, an injection vial, an ampoule, a cartridge, and a syringe.

13 . The primary pharmaceutical packaging according to claim 10 , wherein said primary pharmaceutical packaging is configured to accommodate and store a liquid content substance that has a pH-value in a range of 1 to 11.

14 . The primary pharmaceutical packaging according to claim 13 , wherein the liquid content substance is one of an active substance solution, a buffer solution, and a water for injection purposes.

15 . A semi-finished product, comprising:
a tubular glass, said tubular glass comprising a borosilicate glass comprising the following glass composition (in weight-% on oxide basis):
SiO 2 70-80;
B 2 O 3 8-14;
Al 2 O 3 0;
Na 2 O 0-4;
K 2 O 3-10;
Li 2 O 0;
sum Na 2 O+K 2 O 3-14;
CaO 0-1;
MgO 0-1;
BaO 0-1;
SrO 0-1;
sum CaO+MgO+BaO+SrO 0-2;
ZnO 0-1;
ZrO 2 3.6-14;
TiO 2 0-10; and
at least one refining agent 0.01-2.0;
wherein a weight ratio of ZrO 2 :K 2 O is in the range of 1.2:1 to 1.4:1.

16 . A pharmaceutical combination, comprising:
a primary pharmaceutical packaging consisting of a borosilicate glass comprising the following glass composition (in weight-% on oxide basis):
SiO 2 70-80;
B 2 O 3 8-14;
Al 2 O 3 0;
Na 2 O 0-4;
K 2 O 3-10;
Li 2 O 0;
sum Na 2 O+K 2 O 3-14;
CaO 0-1;
MgO 0-1;
BaO 0-1;
SrO 0-1;
sum CaO+MgO+BaO+SrO 0-2;
ZnO 0-1;
ZrO 2 3.6-14;
TiO 2 0-10; and
at least one refining agent 0.01-2.0;
wherein a weight ratio of ZrO 2 :K 2 O is in the range of 1.2:1 to 1.4:1.

17 . The pharmaceutical combination according to claim 16 , wherein said primary pharmaceutical packaging is at least one of a bottle, a vial, an injection vial, an ampoule, a cartridge, and a syringe.

18 . The pharmaceutical combination according to claim 16 , further comprising a liquid content substance which has a pH value in the range of 1 to 11 within said primary pharmaceutical packaging, wherein said liquid content substance is one of an active substance solution, a buffer solution and a water for injection purposes.

Assignees

• Schott Ag

Inventors

• Kass Christof

Classifications

• C03C3/089 Primary

  containing boron · CPC title

• C03C4/20

  for chemical resistant glass · CPC title

• B65D1/0207

  characterised by material, e.g. composition, physical features · CPC title

• A61J1/06

  Ampoules or carpules (syringe ampoules or carpules A61M5/28) · CPC title

• A61J1/1468

  Containers characterised by specific material properties · CPC title